Feature | May 30, 2013

Houston-based researchers document the value of 3-D mammography as a breast cancer screening technology.

First Large-Scale U.S. Study Validates the Benefits of 3-D Mammography

May 30, 2013 — A recently published clinical study conducted at TOPS Comprehensive Breast Center in Houston, Texas, demonstrates that 3-D mammography (breast tomosynthesis) significantly reduces unnecessary recalls while simultaneously increasing cancer detection.

The study, "Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study," was led by Stephen L. Rose, M.D., and published in the June issue of the American Journal of Roentgenology (AJR). 

The study examined the use of Hologic's 3-D mammography in conjunction with 2-D mammography. The researchers found that 3-D mammography:

  • Reduced recall rates by 37 percent;
  • Increased the detection of cancers by over 30 percent; and
  • Increased the detection of invasive cancers by more than 50 percent.

 

Instead of viewing all the complexities of the breast tissue in a flat image as with a traditional mammogram, 3-D mammography uses multiple low-dose images to create a 3-D view of the breast. 3-D mammography allows the doctor to examine 3-D breast images layer-by-layer.

The 2010 through 2012 study population included 13,856 women who received conventional 2-D mammography screening exams prior to the introduction of Hologic's 3-D mammography technology (breast tomosynthesis) and 9,499 women who received a 3-D mammography screening exam. Images in both time periods were interpreted by six radiologists with an average 12 years of reading experience.  

"We are finding cancerous breast tumors as small as two to three millimeters," Rose said. "We are finding cancer earlier and this will allow us to reduce the amount of treatment patients need."  Rose projects that as 3-D mammography becomes the standard breast cancer screening tool the size of tumors found will get smaller, and accuracy of deciding between benign and cancerous tumors will improve.

    For more information: www.breasttomo.com

 


Related Content

News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Subscribe Now